Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers
Metadata only so far. Questions are answered only with quotes from this document. Source: ctgov, ctgov, retrieved 2026-11-04.
Stopped earlySponsor discontinued the trial
Record metadata
- Phase
- Phase 1
- Status
- Terminated
- Start
- 2024-01-30
- End
- 2026-03-30
- Enrollment
- 1
- Sites
- 1
- Sponsor class
- OTHER
Not in the data yet: a trial card. Cards (population, design, endpoints, result direction, each tied to a quote) arrive with the knowledge layer’s card lane. The fields above are registry or bibliographic metadata, not quotes.
Ask this document
Answers come only from this document’s licensed passages, as highlighted quotes. If it doesn’t say, you get that instead of a guess.
Source text
No passages are loaded for this document yet.